U.S. FDA approves combination HIV pills

By Reuters Staff

(Reuters) - The U.S. Food and Drug Administration on Thursday approved two fixed-dose HIV pills that combine protease inhibitors, both with a boosting agent.

Evotaz from Bristol-Myers Squibb is a once-daily pill containing Reyataz, also known as atazanavir, a protease inhibitor, with the booster cobicistat.

Prezcobix from Janssen Therapeutics combines the protease inhibitor darunavir with cobicistat.

The FDA approved both drugs for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.


Study supports Roche's disputed flu drug Tamiflu

By Kate Kelland

LONDON (Reuters) - A major analysis of one of the world's most fiercely disputed medicines, Roche's Tamiflu, has found it cuts flu symptoms by a day and can help some patients avoid hospital treatment and complications.

But the drug can also have side effects, including nausea and vomiting, which should be balanced against its benefits, researchers who led the study said.